Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (331-340 of 358) with videos related to

Pageof 36
Sort By:
Therapeutic Drug Monitoring|November 15, 2012
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatmentAntonio D'Avolio, Alessia Ciancio, Marco Siccardi, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of TherapyJessica Cusato, Lucio Boglione, Amedeo De Nicolò, et al.
Antioxidants (Basel, Switzerland)|May 25, 2024
Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual TherapyJessica Cusato, Anna Mulasso, Micol Ferrara, et al.
The New Microbiologica|May 29, 2018
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessmentMarco Borderi, Gioacchino Angarano, Andrea Antinori, et al.
Antiviral Therapy|September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational settingAntonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 28, 2020
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)Cristina Mussini, Marco Falcone, Silvia Nozza, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2009
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein revValentina Svicher, Claudia Alteri, Roberta D'Arrigo, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearanceAlessandro Schipani, Marco Siccardi, Antonio D'Avolio, et al.
Journal of Clinical Medicine|June 2, 2021
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE RegistryFrancesco Giuseppe De Rosa, Annagloria Palazzo, Tiziana Rosso, et al.
Ebiomedicine|April 11, 2021
Anti-Tat immunity defines CD4<sup>+</sup> T-cell dynamics in people living with HIV on long-term cARTAntonella Tripiciano, Orietta Picconi, Sonia Moretti, et al.
Pageof 36

Showing results (331-340 of 358) with videos related to

Sort By:
Pageof 36
Therapeutic Drug Monitoring|November 15, 2012
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatmentAntonio D'Avolio, Alessia Ciancio, Marco Siccardi, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of TherapyJessica Cusato, Lucio Boglione, Amedeo De Nicolò, et al.
Antioxidants (Basel, Switzerland)|May 25, 2024
Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual TherapyJessica Cusato, Anna Mulasso, Micol Ferrara, et al.
The New Microbiologica|May 29, 2018
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessmentMarco Borderi, Gioacchino Angarano, Andrea Antinori, et al.
Antiviral Therapy|September 17, 2013
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational settingAntonella d'Arminio Monforte, Nicola Gianotti, Alessandro Cozzi-Lepri, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 28, 2020
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)Cristina Mussini, Marco Falcone, Silvia Nozza, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2009
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein revValentina Svicher, Claudia Alteri, Roberta D'Arrigo, et al.
Antimicrobial Agents and Chemotherapy|October 6, 2010
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearanceAlessandro Schipani, Marco Siccardi, Antonio D'Avolio, et al.
Journal of Clinical Medicine|June 2, 2021
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE RegistryFrancesco Giuseppe De Rosa, Annagloria Palazzo, Tiziana Rosso, et al.
Ebiomedicine|April 11, 2021
Anti-Tat immunity defines CD4<sup>+</sup> T-cell dynamics in people living with HIV on long-term cARTAntonella Tripiciano, Orietta Picconi, Sonia Moretti, et al.
Pageof 36